Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin. Issue 1 (October 2020)

• Record Type: Journal Article
• Authors: Silva-Veiga, Flávia Maria; Miranda, Carolline Santos; Martins, Fabiane Ferreira; Daleprane, Julio Beltrame; Mandarim-de-Lacerda, Carlos Alberto; Souza-Mello, Vanessa
• Is Part Of: Journal of endocrinology. Volume 247:Issue 1(2020)
• Page Start: 11
• Page End: 24
• Publication Date: 2020-10
• Subjects: fructose -- hepatic steatosis -- gut microbiota -- PPAR-alpha -- DPP-4 inhibition; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/JOE-20-0139
• Languages: English
• ISSNs: 0022-0795

Abstract

Abstract : Fructose dietary intake affects the composition of the intestinal microbiota and influences the development of hepatic steatosis. Endotoxins produced by gram-negative bacteria alter intestinal permeability and cause bacterial translocation. This study evaluated the effects of gut microbiota modulation by a purified PPAR-alpha agonist (WY14643), a DPP-4 inhibitor (linagliptin), or their association on intestinal barrier integrity, endotoxemia, and hepatic energy metabolism in high-fructose-fed C57BL/6 mice. Fifty mice were divided to receive the control diet (C group) or the high-fructose diet (HFRU) for 12 weeks. Subsequently, the HFRU group was divided to initiate the treatment with PPAR-alpha agonist (3.5 mg/kg/BM) and DPP-4 inhibitor (15 mg/kg/BM). The HFRU group had glucose intolerance, endotoxemia, and dysbiosis (with increased Proteobacteria) without changes in body mass in comparison with the C group. HFRU group showed damaged intestinal ultrastructure, which led to liver inflammation and marked hepatic steatosis in the HFRU group when compared to the C group. PPAR-alpha activation and DPP-4 inhibition countered glucose intolerance, endotoxemia, and dysbiosis, ameliorating the ultrastructure of the intestinal barrier and reducing Tlr4 expression in the liver of treated animals. These beneficial effects suppressed lipogenesis and mitigated hepatic steatosis. In conclusion, the results herein propose a role for PPAR-alpha activation, DPP-4 inhibition, and their association in attenuating hepatic steatosis by gut-liver axis modulation in high-fructose mice model. These observations suggest these treatments as potential targets to treat hepatic steatosis and avoid its progression.